In the UK, the Prostate Cancer Screening Trial Using Imaging (PROSTAGRAM) using bpMRI (NCT03702439) found that the use of an MRI score >4 on screening bpMRI led to a positive test in 10.6% of the 411 screened men, with 11 clinically significant and 5 clinically insignificant cancers found, leading to a sensitivity of 65% and a specificity of 82%.12 PROSTAGRAM and the Canadian study differ from the current study in that men are excluded from those studies if they have had a recent PSA or previous prostate biopsy. This evidence concerns the gene KLK3 and Familial prostate cancer.